SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced...
Barchart Research What to Expect from ANAB Earnings ANAB Generated May 1, 2026 Current Price $66.76 EPS Estimate $$-1.04 Consensus Rating Strong Buy Average Move 7.09% AnaptysBio's Royalty Cash Machine...
Barchart Research What to Expect from ANAB Earnings ANAB Generated May 1, 2026 Current Price $66.76 EPS Estimate $$-1.04 Consensus Rating Strong Buy Average Move 7.09% AnaptysBio's Royalty Cash Machine...
Barchart Research What to Expect from ANAB Earnings ANAB Generated May 1, 2026 Current Price $66.76 EPS Estimate $$-1.04 Consensus Rating Strong Buy Average Move 7.09% AnaptysBio's Royalty Cash Machine...
WASHINGTON , April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of the original research article titled "Efficacy and Safety of Imsidolimab...
Ruling preserves current contracted royalty rates and rejects Tesaro’s request for any royalty reduction Trial to adjudicate Anaptys’ contract claims and right to seek reversion of Jemperli against...
Focused on protecting and returning value of Jemperli and imsidolimab royalties to shareholders Launches with virtual model, including limited FTEs and minimal operating expenses, and approximately...
Board sets spin-off distribution date for First Tracks Biotherapeutics: expected to occur April 20, 2026, pre-market Stockholders will receive one share of First Tracks Bio common stock for every one...
Inclusive of $80 million in proceeds from private placement by leading investors First Tracks Biotherapeutics to launch with $180 million in cash and two-year cash-runway SAN DIEGO, March 27, 2026...
Anaptys to spin-off biopharma operations into First Tracks Biotherapeutics, with a target distribution date of April 20, 2026 Anaptys to manage the financial collaborations for Jemperli with GSK and...